Launches Europe's First Anthropic Pre-IPO Tracker

21Shares Launches Europe’s first pre-IPO synthetic Anthropic ETP on Tuesday, giving investors continuous, unleveraged exposure to the implied valuation of the privately held AI lab behind the Claude chatbot.

Key Takeaways

21Shares launched Europe’s first pre-IPO synthetic Anthropic ETP on Tuesday
The ETP provides continuous, unleveraged exposure to Anthropic’s implied valuation without representing actual equity in the company
Anthropic has not filed for a public listing and has given no public timeline for one
21Shares has not disclosed the ETP’s valuation benchmark, data provider, management fee or initial assets under management

The Zurich-based issuer announced the product Tuesday, three hours before this report was filed. 21Shares builds exchange-traded products that package exposure to single cryptocurrencies, baskets of tokens and, with this launch, a private technology company’s valuation into a single tradable security listed on European exchanges.

The product does not represent actual equity in Anthropic. It is a synthetic tracker, meaning its price moves with estimates of what Anthropic would be worth if it traded publicly, derived from secondary-market transactions and funding-round data rather than from shares the company itself issues.

Why 21Shares Launches Europe’s First Private AI Valuation Tracker

Anthropic has raised capital in a series of private funding rounds that valued the company in the tens of billions of dollars, but those shares are restricted to venture investors, employees and select institutions.

Retail investors have no legal route to buy Anthropic stock because the company has not filed for an initial public offering.

A synthetic ETP sidesteps that restriction by tracking a reference valuation rather than holding actual shares, similar to how some crypto exchange-traded products track an index rather than holding every underlying token in equal weight. The approach mirrors structures that have emerged for other sought-after private AI names, letting European retail brokerages offer something close to pre-IPO exposure without the regulatory hurdles of direct private placements.

Also Read: HCLTech Becomes Anthropic’s Top Claude Partner, Builds New AI Business Unit

21Shares Launches Europe Into A Retail Product Category

Anthropic’s rise from a 2021 OpenAI spinoff to one of the most capitalized private companies in the world has made it a prime target for this kind of product.

The lab’s enterprise push accelerated through 2026 with partnerships across banking, government and consulting, including a global partnership with HCLTech signed this week that the Indian IT services firm credited for record quarterly deal bookings.

Anthropic has not filed for a public listing and has given no public timeline for one, leaving secondary markets and estimate-based products like 21Shares’ ETP as the only retail-accessible proxy for its worth. Record quarterly deal bookings are not a reported revenue figure.

What Determines The Price Investors Actually See

21Shares has not disclosed the exact valuation benchmark or data provider feeding the ETP’s reference price, nor the product’s management fee or initial assets under management.

Investors buying the ETP are exposed to whatever methodology 21Shares uses to mark Anthropic’s valuation between funding rounds, a key risk given that private valuations can lag or overshoot public sentiment by months.

For the valuation to make sense, the benchmark must reflect the secondary-market transactions and funding-round data it is designed to track. The product’s performance will also depend on whether Anthropic eventually goes public, merges or shuts down, any of which could trigger a redemption or delisting event not yet specified in the launch materials.

Retail demand for exposure to Anthropic, OpenAI and other frontier labs has grown as their enterprise deal volumes expand, and 21Shares is betting European investors want that exposure now rather than waiting years for a possible IPO.

That is an expectation of investor demand, not a stated revenue forecast.